R&D portfolio management software decides which research and product development projects get funded, staffed and pushed through the next gate. The market splits into four shapes: enterprise PPM suites with an R&D heritage (Planisware, Planview), innovation management platforms (ITONICS, Wellspring's Accolade), valuation and simulation tools (Captario), and lighter portfolio and capacity tools (Meisterplan, Triskell, focused scoring workspaces). The right choice depends less on features than on whether your problem is modeling the pipeline or agreeing what to fund.
This comparison is written for the person who owns the pipeline review, usually a head of R&D portfolio, an NPD PMO lead or a VP of R&D operations, and who has been told the spreadsheet will not survive another budget cycle.
Key takeaways
- R&D portfolios differ from IT portfolios in three ways: long horizons, a probability of success on every project, and gate decisions that kill most ideas on purpose.
- Planisware Nova and Planview's new product development solution are the enterprise suites; both are quoted and usually come with a services line.
- Innovation platforms such as ITONICS and Accolade (now owned by Wellspring, since February 2024) are strongest at the front end: ideas, technology scouting and roadmaps.
- Simulation tools such as Captario SUM value a pharma pipeline under uncertainty; they complement a portfolio tool rather than replace it.
- If the real gap is a ranked, funded list that can be staffed, a scoring model plus a capacity plan by role settles it long before a suite goes live.
What is the best R&D portfolio management software?
The best R&D portfolio management software is the one built for the decision you struggle with most. For large, stage gated pipelines with long cost models, Planisware Nova or Planview. For the idea and technology front end, ITONICS or Accolade. For pharma valuation under uncertainty, Captario. For ranking, funding and staffing the portfolio quickly, a lighter tool with published pricing.
That sounds like a hedge, so here is the same answer as a table. It compares vendors by what they are built to do, which is how the evaluation should start. Feature grids come later.
| Tool | Shape | Built for | Pricing | Watch out for |
|---|---|---|---|---|
| Planisware Nova | Enterprise PPM, R&D heritage | Stage gated product development pipelines with long horizon cost and resource models | Quoted, with configuration services | Implementation effort and consulting day rates reviewers call high |
| Planview (new product development solution) | Enterprise SPM | Diversified companies where R&D shares one portfolio with IT and operations | Quoted, role based seats | A broad product family; confirm which Planview product is in the proposal |
| ITONICS | Innovation management platform | Technology radars, idea funnels, roadmaps and an innovation portfolio view | Quoted | Lighter on detailed resource scheduling than a PPM suite |
| Accolade (Wellspring) | Innovation and NPD management | Idea to launch processes with gate reviews for product companies | Quoted | Ownership changed in 2024; ask about the product roadmap under Wellspring |
| Captario SUM | Portfolio simulation | Pharma and biotech teams valuing a pipeline with probability of success and risk | Quoted | A valuation engine, not a place to run projects or capacity |
| Meisterplan | Portfolio and capacity planning | What if scenarios on people and budget across the pipeline | Per schedulable resource, users free | Not a stage gate or valuation tool on its own |
| Triskell | Configurable PPM | A preconfigured NPD model with phase gates for mid-sized product organizations | Quoted | Value depends on how much of the preset model fits your process |
| Portfolio Hub | Focused portfolio workspace | A weighted scoring model, a funding line, a twelve month capacity plan by role and gate packs | Published, per workspace | No pipeline valuation or detailed scheduling; pair it with a finance model |
Swipe to see more →
We publish the last row, so treat it as our view and test it like any other. Every other row describes what the vendor itself sells the product for, not a ranking.
Why R&D portfolios need different software than IT portfolios
A general PPM tool assumes that most approved projects will finish. R&D assumes the opposite. A pharma pipeline expects most compounds to fail before approval, and a consumer goods innovation funnel is designed to kill the majority of concepts at the first two gates. Software that treats a cancelled project as a failure, rather than as the process working, will produce reports nobody trusts.
| Dimension | Typical IT portfolio | Typical R&D portfolio | What the software must handle |
|---|---|---|---|
| Horizon | One to three years | Three to fifteen years | Multi-year cost and resource curves per phase |
| Uncertainty | Scope and schedule risk | Technical and commercial probability of success | Risk adjusted value, not just a point estimate |
| Cancellation rate | Low, cancellations are exceptions | High by design at early gates | Gate decisions as normal events, with the reason kept |
| Value measure | Benefits, cost savings, risk reduction | Risk adjusted NPV, peak sales, strategic fit | Several value measures scored side by side |
| Scarce resource | Developers and architects | Scientists, labs, pilot lines, clinical capacity | Capacity by specialized role and facility, by month |
Swipe to see more →
If three or more of the right-hand column describe your portfolio, a tool that was designed for IT demand management will fight you at every review. That is the practical reason Planisware and Planview both sell R&D specific packages, and why our wider PPM software comparison treats R&D as its own category.
How do you prioritize an R&D portfolio?
You prioritize an R&D portfolio by scoring every project on the same weighted criteria, usually risk adjusted value, strategic fit, probability of success and resource demand, ranking the list, and drawing a funding line at the real budget. Projects below the line are paused or killed at their next gate, and the capacity plan confirms the funded list can actually be staffed.
The method matters more than the tool, and most teams already know the pieces. What goes wrong is the sequence. A pipeline review that ranks projects without checking scientist and lab capacity approves a list that cannot be delivered, and the slippage shows up six months later as every project running late at once. The order that works:
- Agree the criteria and weights once a year, with finance and the business units in the room, and write them down.
- Score every active and proposed project on those criteria, including the ones nobody wants to question.
- Rank and draw the funding line at the budget you actually have, not the one you asked for.
- Check capacity by role and month for everything above the line. Where a specialist role is overbooked, the lowest ranked project using it moves down.
- Take the result to the gate meetings as the default decision, which the gate committee can overrule with a written reason.
Steps one to three are the job of a project prioritization tool; step four is a capacity planning tool; step five is where stage gate software earns its keep. Enterprise suites do all five in one system. Lighter tools do one or two of them well, and that is often enough for the first year.
How much does R&D portfolio management software cost?
Most R&D portfolio software is quoted rather than priced publicly, and enterprise suites add configuration services on top of the license. The public reference points are few: Capterra lists Planisware Orchestra, the vendor's lighter product, at $45 per user per month, and Meisterplan prices by schedulable resource with users free. Budget the services line separately from the license.
| Pricing model | Who uses it | What grows the bill | Question to ask |
|---|---|---|---|
| Quoted enterprise license with services | Planisware Enterprise and Nova, Planview | Named users by license type, modules, configuration days | What is the services estimate in days, with a written scope? |
| Quoted platform subscription | ITONICS, Accolade, Captario | Modules, users and the size of the idea or project base | Which modules does the first year actually need? |
| Per schedulable resource | Meisterplan | Every person you plan capacity for | Do contractors and external labs count as resources? |
| Per user, directory listed | Planisware Orchestra (reported $45 per user a month) | Every seat, and moving up an edition | Which roles can work on a cheaper license? |
| Per workspace, published | Portfolio Hub | A larger plan for more initiatives, roles or gate packs | None; limits are on the pricing page |
Swipe to see more →
Our Planisware pricing guide works the reported Orchestra figure into a first-year budget and lists the lines that move an enterprise quote. For partnered programs, remember that the portfolio tool is not the system of record for the money that depends on external parties. Milestone payments and option dates written into licensing and CRO agreements belong in contract management software that alerts the owner before a deadline passes, with the portfolio tool linking to that record rather than copying it.
Do you need a separate tool for stage gate reviews?
You need a separate stage gate tool only if your portfolio suite cannot hold gate criteria, decisions and evidence per project. Planisware, Planview and Accolade include gate workflows. Innovation platforms and capacity tools often do not, so teams pair them with a gate tool or a structured decision pack produced for every review.
The test is simple. After your last three gate meetings, could someone outside the committee see what was decided, on what evidence and why? If the answer lives in slide decks and inboxes, the gap is real, and it matters more in R&D than anywhere else because the kill decisions are the most valuable data the portfolio produces. Our guide to the stage gate process covers what each gate should require.
Six things to prove in a trial, on your own pipeline
Every vendor on the list runs a clean demo on a clean pipeline. Ask for a proof of concept instead, load twenty real projects with their real phases and roles, and check these in front of the people who run the pipeline review.
| Check | What to do | What a pass looks like |
|---|---|---|
| Probability of success | Enter a success rate per phase for three projects | Value and rank change accordingly, without a custom report |
| A kill is a normal event | Stop one project at a gate with a reason | The reason is kept, capacity is released, reports stay clean |
| Specialist capacity | Load your real scientist, lab and pilot line roles | Shortfall shows per role per month for the funded list |
| The funding line | Set the budget below total demand | The list splits into funded and not funded, with cumulative cost |
| PMO owns the weights | Change a criterion weight in the session | The ranking reorders in front of you, without a consultant |
| Data comes out | Export the register, scores and capacity plan | Excel or CSV on demand, ready for finance |
Swipe to see more →
When a suite is worth it, and when it is not
A full R&D suite earns its cost when hundreds of projects, many sites and a long-horizon financial model must live in one governed system, and when you have the internal team to own the configuration after the consultants leave. Large pharma, aerospace and diversified manufacturers usually fit that description, which is why Planisware reports working with 18 of the top 20 pharma companies.
It is not worth it, yet, when the organization has never agreed its scoring criteria, when the pipeline review still argues about which projects exist, or when the budget decision is due before an implementation could finish. In that situation the fastest path is a scoring model, a funding line and a capacity plan that the steering group can use at the next review. That also produces the clearest requirement list you could hand a suite vendor later.
If that describes your next pipeline review, you can open a portfolio workspace, load the projects you already track, and bring a ranked, funded and staffed list to the meeting. The plans are published, so the cost question is answered before the first call.